NEW YORK (GenomeWeb) – The recent addition of exosome technologies to the portfolio of Swiss multinational life sciences company Lonza reflects a growing belief in industry and academia that the cell-derived vesicles could be the biomarker of choice for non-invasive tests and new therapies.
Lonza, headquartered in Basel, Switzerland, announced in mid-May that it had acquired HansaBioMed Life Sciences, a Tallinn, Estonia-based supplier of technology and services for exosome research, for an undisclosed sum, while simultaneously investing in Exosomics, a Siena, Italy-based firm developing next-generation sequencing-based cancer tests.
Behzad Mahdavi, Lonza’s vice president of strategic innovation and alliances, said that the deals represent Lonza’s first foray into the nascent arena of exosome-based diagnostics and therapeutics, though one it sees as complementary to its existing expertise and target markets.
“Exosomes are considered to have potential as therapeutic agents, vehicles for drug delivery, diagnostic biomarkers, and active agents in consumer care products, making them compatible with current Lonza markets,” said Mahdavi.
“With Lonza’s capabilities in large scale cell-culture manufacturing, we are well suited to develop the processes needed for the commercial scale production for exosome applications, an additional logical step in the advancement of this field,” he said.
Founded in 1897 in